TABLE 3

Comparison of Short- and Long-Term Outcomes in Patients Addressed to Early FI (Group B) and in Controls (Group A)

Controls (N = 38)Volume Expansion (N = 38)RR/GMR (95% CI)P
Outcomes during acute phase
 Death, N (%)2 (5.2)0 (0)NA.49
 CNS involvement, N (%)9 (23.7)3 (7.9)0.33 (0.10–1.14).06
 Need for RRT, N (%)22 (57.9)10 (26.3)0.45 (0.25–0.83).01
 Days of hospitalization, median (IQR)12 (7–18)9 (7–12)0.75 (0.59–0.96).02
 Days in PICU, median (IQR)a8.5 (3.5–15.5)2 (1–4.5)0.31 (0.12–0.82).02
Long-term outcomes
 Extrarenal sequelae, N (%)1 (2.6)1 (2.6)NA.99
Renal sequelae
 Major (CKD II-V), N (%)1 (2.6)0 (0)NA.49
 Minor (CKD I), N (%)12 (34.3)5 (13.2)0.38 (0.15–0.98).03
Total patients with long-term sequelae, N (%)b15 (39.5)5 (13.2)0.33 (0.13–0.83).01
  • GMR, geometric mean ratio; NA, not applicable.

  • a 8 patients in group A and 8 patients in group B.

  • b Because renal and extrarenal sequelae are not mutually exclusive, the total of long-term sequelae exceeds the number of patients.